Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 170
- Registration Number
- NCT02621021
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
- Conditions
- Stage IIIC Cutaneous Melanoma AJCC v7Metastatic MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7Stage IIIB Cutaneous Melanoma AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentBiological: Therapeutic Tumor Infiltrating Lymphocytes
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02500576
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02489266
IL-2 for Multi Drug Resistant Nephrotic Syndrome
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- Istituto Giannina Gaslini
- Target Recruit Count
- 5
- Registration Number
- NCT02455908
- Locations
- 🇮🇹
Istituto Giannina Gaslini, Genova, Italy
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
- Conditions
- Metastatic Thyroid Cancer
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02390739
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
- Conditions
- Cervical CancerAnal CancerOropharyngeal CancerVaginal CancerPenile Cancer
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT02280811
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2018-08-21
- Target Recruit Count
- 41
- Registration Number
- NCT02265809
- Locations
- 🇬🇧
Wellcome Trust Clinical Research Facility, Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
- Conditions
- Cervical CancerMelanomaBreast CancerBladder CancerRenal Cancer
- Interventions
- Biological: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT02153905
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Advanced Non-Small Cell Lung CancerAdvanced NSCLCSquamous Cell CarcinomaAdenosquamous CarcinomaAdenocarcinoma
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT02133196
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
- Conditions
- MelanomaCervical CancerBreast CancerRenal CancerUrothelial Cancer
- Interventions
- Biological: Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT02111850
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.